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Case presentation
A 63-year-old, hypertensive, nondiabetic man with a 4-year history of
gout was hospitalized because of painful swelling of his right foot. His
blood pressure had been treated with nifedipine, 20 mg orally, three
times daily. On admission, the patient was normotensive (blood pres-
sure, 140/85 mm Hg) and had no clinical signs of congestive heart failure
or volume depletion. Physical examination revealed erythema and
soft-tissue swelling of the dorsum of the right foot with metatarsal
tenderness. Laboratory data showed mild azotemia with a BUN level of
23 mg/dl; serum creatinine, 1.8 mg/dl; creatinine clearance, 70 mllmin;
serum potassium, 4.1 mEq/liter; serum bicarbonate, 24 mmol/liter; and
serum uric acid, 13.2 mg/dl. Roentgenographic findings were consistent
with erosive gout, and a diagnosis of acute gouty attack was made.
Indomethacin, 50 mg orally three times daily, was begun. The patient's
symptoms improved rapidly, but within 4 days, the BUN rose to 51
mg/dl; serum creatinine, 2.4 mg/dl; serum potassium, 6.6 mEq/liter; and
serum bicarbonate, 27 mmollliter; the creatinine clearance decreased to
36 mI/mm, with a fractional excretion of sodium of 0.06% and a urinary
potassium concentration of 21 mEq/liter. The urinary sediment was
unremarkable. The patient's blood pressure ranged from 140/85 to
150/90 mm Hg and no major changes in urinary output were noted.
Indomethacin treatment was discontinued and replaced by colchicine.
The patient's renal function and serum potassium level returned to
baseline values within 4 days.
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cine, Bronx, New York): Let me summarize the pertinent
findings in this case. When an elderly patient with a history of
hypertension, gout, and mild renal insufficiency was given
indomethacin therapy, his renal function promptly declined, as
illustrated by a rise in the BUN and creatinine. Furthermore, he
developed hyperkalemia without acidosis and without any
symptoms or notable change in blood pressure or urinary
output. The urinalysis was normal, and the fractional excretion
of sodium was less than 1%. Finally, all these features promptly
receded when the nonsteroidal drug was discontinued. Which
of the changes in blood chemistries represent common features
of the renal side effects of nonsteroidal antiinflammatory drugs
(NSAIDs)?
I would like to stress that renal side effects of NSAIDs are
extremely uncommon. It is estimated that 50 million Americans
take an NSAID at some time each year, yet we only see a small
number of patients with renal side effects [1—3], the most
common of which are listed in Table 1. The list includes acute,
reversible, vasomotor renal failure with hyperkalemia, which
the patient under discussion illustrates. Furthermore, a modest
decline in renal excretion of salt and water can occur but
usually is inconsequential and goes unrecognized. Occasionally
the fluid retention and decreased generation of vasodilatory
prostaglandins caused by NSAIDs can interfere with diuretics
and antihypertensive therapies. All these side effects of
NSAIDs can be explained by their inhibition of prostaglandin
synthesis and the resulting interference with the physiologic
actions of prostaglandins in the kidney [1, 2, 4—li].
Another group of side effects of nonsteroidal drugs, even
more rarely encountered, include the acute interstitial nephrit-
ides with and without renal failure, and the nephrotic syndrome
with or without interstitial nephritis and with or without renal
failure [12—16]. Finally, long-term abuse of analgesics including
NSAIDs might play a part in the pathophysiology of analgesic-
induced nephropathy [17, 18]. I shall limit my discussion
predominantly to the effects of NSAIDs on glomerular filtration
and on renal electrolyte excretion. Renal side effects of
NSAIDs and the role of prostaglandins in renal function have
been reviewed extensively [1, 2, 4, 5, 12, 13, 19—22].
Pathophysiology of prostaglandins
The physiologic actions of prostaglandins in the kidney help
explain the more common side effects of NSAIDs. All NSAIDs
are cyclooxygenase inhibitors and decrease the generation of
prostaglandins [23]. Prostaglandins are not present in stored
form in tissues but are locally acting autacoids generated "as
needed" by stimulation of cellular arachidonic acid release [7,
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Table 1. Renal side effects of NSAIDs
Acute reversible "vasomotor" renal failure
Interference with renal excretion of:
Water
Sodium
Potassium
Interference with:
Antihypertensive therapy
Diuretic therapy
Acute interstitial nephritis with or without renal failure
Nephrotic syndrome with or without interstitial nephritis, with or
without renal failure
Chronic renal injury "analgesic nephropathy"
11, 19, 20]. Stimuli for arachidonic acid release include a large
number of vasoactive hormones and cytokines, as well as
hypoxia, ischemia, and cellular disturbances of a mechanical
nature [7, 8, 10, 11, 20]. Arachidonic acid is converted to the
intermediate prostaglandin endoperoxides PGG2-PGH2 by
prostaglandin endoperoxide synthase (PGH-synthase). The
specific prostanoid generated depends on further tissue-specific
metabolism of the endoperoxide. The kidney generates predom-
inantly PGI2, PGE2, and some PGF2Ø, [7, 8, 11, 19, 20]. The
major roles of prostaglandins (PGI2 and PGE2) in renal function
include modulation of the following; renal blood flow and
glomerular filtration rate, renin release, the concentrating
mechanism, and excretion of sodium and potassium. I stress the
word modulation because prostaglandins are not primary regu-
lators of organ function, but rather local modulators of systemic
regulation. Because they act at the site of their generation, the
specific sites of their synthesis within the nephron are important
and should coincide with their effector sites [8]. As immunohis-
tology and microdissection studies illustrate, the major sites of
cyclooxygenase in the kidney comprise the arterial tree, includ-
ing the afferent and efferent arterioles, the glomerulus with
mesangial and endothelial cells, and along the tubule, predom-
inantly the collecting tubule [8, 24, 25]. Furthermore, interstitial
cells adjacent to the thick ascending limb of Henle's loop and in
the medulla are rich in PGH synthase [7, 8, 11, 24]. The sites of
prostaglandin generation coincide with the localization of pros-
taglandin receptors [26]. Thus the prerequisites for an autacoid
are fulfilled in the renal vasculature, including the glomerulus,
Henle's loop, the collecting tubule, and the renal medullary
interstitium.
Effects of NSAIDs on renal blood flow and glomerular
filtration
Let me turn to the role of prostaglandins as modulators of
glomerular blood flow and filtration [8—10]. The rates of these
physiologic parameters are predominantly determined by the
tonus of the afferent and efferent arterioles and are "fine tuned"
by the intercapillary mesangial cells, Under normal, euvolemic
conditions, prostaglandins play a negligible role in maintaining
renal and glomerular blood flow. However, numerous in-vivo
clearance and micropuncture studies and elegant microperfu-
sion studies of interlobular, afferent, and efferent arterioles and
studies with isolated glomeruli have shown that during activa-
tion of vasoconstrictor systems—such as angiotensin II, nor-
epinephrine, vasopressin, and endothelin—local prostaglandin
formation attenuates the vasoconstrictor effects and thereby
maintains renal blood flow and glomerular filtration [8, 10, 27,
28]. Furthermore, the vasoconstrictor hormones stimulate local
production of vasodilatory prostaglandins, resulting in a feed-
back loop between vasoconstrictors and prostaglandins [8—10,
28, 29]. In vitro this loop is illustrated by the ability of
angiotensin II to stimulate prostaglandin production by mesan-
gial cells, isolated glomeruli, and arterioles [8, 10, 28]. In vivo
the loop can be demonstrated in clearance and micropuncture
studies with determination of PGE2 content in early proximal
tubular fluid reflecting glomerular prostaglandin generation [301.
Endothelin is another locally generated vasoconstrictor that
stimulates prostaglandin synthesis [31, 32]. Recent studies from
Ballerman's laboratory have elegantly illustrated that co-cul-
ture of mesangial cells with glomerular endothelial cells mark-
edly increases prostaglandin generation by mesangial cells [31].
This increase, which can be inhibited by a neutralizing antibody
against endothelin, demonstrates that mesangial prostaglandin
generation can be influenced by endothelin generated by the
directly adjacent glomerular endothelial cells.
In summary, a balance exists between the vasoconstrictors,
such as angiotensin II, vasopressin, norepinephrine, and endo-
thelin, and the vasodilatory prostaglandins and, of course,
endothelium-derived relaxing factor (EDRF) [33]. If NSAIDs
are administered, the vasodilatory components of PGE2 and
PG!2 are eliminated, and the balance is tipped in favor of the
vasoconstrictors (Fig. 1). Vasoconstrictor activity, of course,
has to be present for the balance to be tipped. This fact is
illustrated by numerous studies in experimental animals and
also in humans [9, 101. For example, studies by Favre et a!
showed that under euvolemic conditions the administration of
indomethacin does not produce a change in plasma creatinine
[34]. Similarly, administration of the diuretic triamterene alone
does not alter the creatinine level. When the diuretic is super-
imposed on prostaglandin inhibition by indomethacin, however,
the serum creatinine level promptly increases. Discontinuation
of the nonsteroidal agent returns the creatinine level promptly
to baseline and illustrates that prostaglandin synthesis is impor-
tant in maintaining renal blood flow during conditions of volume
depletion with increased vasoconstrictor activity. Commonly
encountered clinical conditions with increased vasoconstrictor
activity include congestive heart failure, hepatic cirrhosis,
nephrotic syndrome, hypertension, sepsis, anesthesia, diabetes
mellitus, and volume depletion secondary to diuretics or extra-
renal fluid losses [1—4, 21, 22, 35, 36]. Under these conditions,
creatinine clearance can decline when nonsteroidal antiinflam-
matory drugs are administered (Table 2).
Another group that seems to be at risk for developing the
acute vasomotor decline in renal function when NSAIDs are
administered are patients with chronic renal insufficiency. The
incidence of N SAID-induced azotemia in patients with baseline
renal insufficiency has been reported to be as high as 30%
[36—38]. The susceptibility of patients with renal insufficiency to
NSAID-induced declines in renal function has been explained
as follows: Renal disease leads to increased prostaglandin
production, which contributes to the maintenance of renal
blood flow and glomerular filtration [4, 10, 39—42]. Thus inhibi-
tion of the increased prostaglandins results in a loss of the
compensatory renal blood flow and a decline in renal function.
Typical features of NSAID-induced acute vasomotor renal
failure include: the presence of one or more risk factors, modest
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Vasoconstrictors Balance Vasodilators
Vasodilators
Fig. 1. Schematic illustration of the influence
of NSAIDs on the balance between
vasoconstrictors and vasodilators. All,
angiotensin II; AVP, arginine vasopressin;
norepi, norepinephrine; EDRF, endothelium-
derived relaxing factor; POE2, prostaglandin
E2; P0!2, prostacylin.
Table 2. Risk factors for acute vasomotor renal failure with NSAIDs
Volume depletion
Anesthesia
Congestive heart failure
Hepatic cirrhosis
Nephrotic syndrome
Infections
Diabetes mellitus
Advanced age
Renal insufficiency of any cause
salt and water retention with weight gain (1—2 kg), decreased
urinary output, a low FENa (<1.0%), a benign urinary sedi-
ment, and prompt reversibility upon discontinuation of the
NSAID.
Pharmacokinetic considerations
Are these pathophysiologic considerations sufficient to ex-
plain the increased incidence of acute vasomotor renal insuffi-
ciency in elderly patients taking diuretics, who have congestive
heart failure or renal insufficiency? I submit that other factors
also might be important, especially certain aspects of the
pharmacokinetics of NSAIDs (Table 3). Such factors can be
altered in the patients at risk for developing renal side effects of
NSAIDs and can increase blood levels of the NSAIDs. Most
NSAIDs undergo hepatic deactivation by hydroxylation, glu-
Table 3. Factors that influence effects of NSAIDs
Altered volume of distribution (e.g., reduced total body water,
increased body fat)
Decreased protein binding (e.g., low serum albumin, chronic renal
insufficiency)
Decreased metabolism and excretion
Oral versus parenteral administration
coronidation, and conjugation prior to excretion by the kidney
[23]. Renal excretion accounts for 50% to 90% of the conjugated
metabolites and from negligible amounts to as much as 50% of
the unchanged drug. Both native NSAIDs and their metabolites
are excreted by filtration and proximal tubular secretion. Thus,
during conditions of reduced renal blood flow and filtration,
renal excretion of the NSAID, both unmetabolized and metab-
olized, can decrease to some extent and possibly result in
increased blood levels of metabolites of the NSAID and to a
lesser extent of the unmetabolized NSAID [43].
Another factor leading to increased blood levels of N SAID is
an altered volume of distribution. Elderly patients have reduced
total body water. Furthermore, most NSAIDs are highly albu-
min bound (greater than 90%). Elderly patients, especially
those with chronic illnesses, often have lower albumin levels;
the resulting reduction in protein binding of the NSAID can
produce higher free-drug levels. This scenario applies espe-
cially to patients with renal insufficiency, in whom "uremic"
NSA ID
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retention products also compete for albumin binding. Due to
such competition, the circulating levels of free drug generally
are increased in renal insufficiency for agents that are albumin
bound [43]. The metabolites of NSAIDs, retained because of
decreased renal excretion, may also compete for albumin
binding of the parent NSAID. Elderly patients, patients with
congestive heart failure, and obviously patients with impaired
liver function can exhibit decreased hepatic NSAID metabolism
with increased drug half-lives, and hence can manifest unex-
pectedly high drug levels and excessive prostaglandin inhibition
[36, 37, 44, 45]. Finally, parenteral administration of nonsteroi-
daIs, which can produce high peak blood levels and thereby
increase prostaglandin inhibition, can result in acute renal side
effects [46]. 1 think it is important to remember these basic
considerations of drug metabolism when administering nonste-
roidal agents to elderly, sick patients; to patients with reduced
liver function; to those with low albumin levels; or to patients
with reduced renal function. These conditions can result in
higher-than-anticipated free levels of the NSAID and a pro-
longed half-life, and thus to more marked inhibition of pros-
taglandin synthesis than would be expected from a similar
dosage in a healthy person. Thus the dose of the NSAID
probably should be reduced in this group of patients. The
patient under discussion is a good illustration. He was elderly
and had modest renal insufficiency, gout, and hyperuricemia.
With respect to the last factor, NSAIDs and their metabolites
may compete with uric acid for renal tubular secretion [47]; if
so, high levels of uric acid could lead to increased drug levels
and excessive prostaglandin synthesis inhibition.
Nonenzymatic generation of prostanoids
Let us now examine another possibility that could account
for the increased vasoconstriction observed with NSAIDs in
patients with chronic renal disease and in patients with mark-
edly decreased renal blood flow and ischemia. Roberts' group
described a nonenzymatic pathway for arachidonic acid metab-
olism leading to PGF2-like products [48]. This nonenzymatic
conversion, mediated by free oxygen radicals, results in perox-
idation of arachidonic acid. Renal ischemia and a variety of
renal insults and disease processes cause increased free oxygen
radical production and lipid peroxidation [491. Under these
conditions, one would therefore expect increased production of
these PGF2a-like metabolites. Indeed this effect was demon-
strated in experimental post-ischemic renal injury in rats [50].
During generation of free oxygen radicals and during inhibition
Fig. 2. Hypothetical scheme for the
nonenzymatic production of vasoconstrictor
PGF2,-like prostanoids during injury
secondary to release of arachidonic acid (AA)
and free oxygen radicals. Inhibition of the
cyclooxygenase-generated vasodilators PGE2
and PGI2 would further favor
vasoconstriction.
Table 4. Potential factors contributing to hyperkalemia with
NSAIDs
Decreased renin and aldosterone secretion
Decreased distal tubular flow rate
Decreased distal tubular Na delivery
Direct effects on distal tubular K secretion (?)
of cyclooxygenase by an NSAID, more arachidonic acid would
be available for peroxidation. Could this be relevant to the
decline in renal blood flow and GFR frequently observed when
NSAIDs are administered to patients with renal disease? Taka-
hashi et al have shown that the PGF2,-like peroxidation prod-
ucts have major vasoconstrictor effects [50]. Intrarenal artery
infusion of 8-epi-PGF2,, a representative peroxidation metabo-
lite, into euvolemic rats significantly reduced single-nephron
glomerular filtration rate and intraglomerular hydrostatic pres-
sure, and predominantly increased afferent arteriolar resistance
[50]. Thus in patients with underlying ischemic or inflammatory
renal injury, the addition of an NSAID cyclooxygenase inhibi-
tor not only decreases production of vasodilatory prostaglan-
dins, but also results in the nonenzymatic formation of vaso-
constrictor metabolites of arachidonic acid (Fig. 2). These
metabolites could further jeopardize renal blood flow and
glomerular filtration, resulting in a self-perpetuating vicious
cycle. These studies prompted another interesting observation:
the peroxidation products of arachidonic acid interact with
thromboxane receptors [50]. Their effect on the kidney thus can
be blocked by thromboxane receptor antagonists [50]. This
relationship might help explain why under certain experimental
conditions thromboxane receptor antagonists are more effective
than thromboxane synthesis inhibitors in improving renal func-
tion [6]. The thromboxane receptor antagonist would block the
effects of both thromboxane and the novel peroxide metabolites
of arachidonate, whereas the thromboxane synthesis inhibitor
would only block thromboxane.
NSAIDs and hyperkalemia
Another complication of NSAIDs illustrated by our patient is
hyperkalemia (Table 4). Hyperkalemia has occurred in patients
at risk for developing NSAID-induced renal insufficiency [51—
55]. The hyperkalemia can occasionally reach life-threatening
levels. The major explanation given for the hyperkalemia
induced by NSAIDs is suppression of renin and aldosterone
secretion [53, 55]. Both PGI2 and PGE2 stimulate renal renin
Injury
Thyclo N SAIDfree oxygen radicals7/
peroxidation oxygenase
V
PGF2a-like products
N
PGI2,PGE2
Vasoconstriction
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release, and inhibition of prostaglandins by NSAIDs lowers
renjn secretion and leads to a modest decline in aldosterone [8,
10, 56]. Decreased prostacyclin generation might contribute to
the pathophysiology of the hyporenin-hypoaldosterone syn-
drome [8, 10]. Irrespective of the potential contribution of
prostaglandin deficiency to this syndrome, a number of studies
have shown that prostaglandin inhibition by NSAIDs can
contribute to the development of hyperkalemia, especially in
patients with the hyporenin-hypoaldosterone state and those
taking converting enzyme inhibitors [53—56]. However, I doubt
that NSAID-induced prostaglandin inhibition and the conse-
quent decrease in aldosterone production fully account for the
NSAID-induced hyperkalemia. In 2 patients with Addison's
disease, who were maintained on a fixed dosage of mineralo-
corticoid, the administration of an N SAID promptly decreased
the urinary Na and K excretion, and in one patient led to
hyperkalemia (Schambelan M, personal communication). Thus
suppression of aldosterone alone is an insufficient explanation
for the hyperkalemia. Additional contributory factors likely
include reductions in distal tubular flow rate and sodium deliv-
ery, both of which can limit potassium secretion [57, 58].
Urinary flow rate in the distal tubule is a major determinant of
potassium secretion. A marked reduction in distal tubular
sodium delivery also can limit potassium secretion. Pros-
taglandin synthesis inhibition could decrease distal sodium
delivery and flow by decreasing glomerular filtration rate and
increasing reabsorption of sodium in the loop of Henle. Fur-
thermore, the increased action of antidiuretic hormone that
results from inhibition of prostaglandin synthesis [59] further
decreases flow rate and thereby lowers the patient's ability to
secrete potassium. Even these considerations might be inade-
quate to fully explain the hyperkalemia that occurs in some
patients taking an N SAID, however. Most of these patients do
not become oliguric, and the urinary sodium concentration,
while low, should be sufficient to allow for adequate potassium
secretion.
I would like to speculate that prostaglandins have an addi-
tional, more direct effect on K secretion that might explain the
occasional hyperkalemia seen in patients taking NSAIDs. Re-
cently a high-conductance K channel was described in the
luminal membrane of collecting tubular principal cells [60]. This
"maxi" channel is voltage-dependent and regulated by intra-
cellular calcium and arachidonic acid metabolites, including
PGE2. These "maxi" K channels may have little influence on
K secretion under physiologic conditions; they may predom-
inantly cause potassium secretion during cell swelling to regu-
latecell volume. However I propose that these "maxi" chan-
nels also might play a role in the reduced potassium excretion
observed with NSAID administration. Increased distal and
collecting tubular water reabsorption under the influence of
ADH would result in cell swelling and also increase the open
probability of the K channels. Both these mechanisms may be
mediated in part by intracellular arachidonic acid release and
PGE2 formation [60]. Inhibition of PGE2 synthesis by NSAIDs
therefore would decrease the probability of open "maxi"
channels and could potentially decrease K secretion. At
present this additional explanation for the occasionally ob-
served hyperkalemia induced by NSAIDs remains hypotheti-
cal. Finally, I would like to point out again that most patients
who develop hyperkalemia while taking an NSAID have under-
lying risk factors for hyperkalemia, especially hyporeninemia
and renal insufficiency [51, 52, 58]. In this group of patients the
NSAID might unmask an underlying problem of K excretion.
Effects of NSAIDs on salt and water balance and blood
pressure
As noted, physiologic actions of PGE2 also include inhibition
of sodium chloride reabsorption in the thick ascending ioop of
Henle and in the collecting tubule [8]. Furthermore, PGE2
antagonizes the antidiuretic effect of vasopressin in the collect-
ing tubule [8, 59]. Predictably, then, inhibiting PGE2 synthesis
by NSAIDs increases both NaCI and water reabsorption. This
alteration usually results in a net fluid retention of 0.5 to 1.0 liter
and a corresponding weight gain of 1 to 2 pounds. Furthermore,
NSAIDs can reduce the effectiveness of loop diuretics [61—63].
In general this reduction is of little consequence, but it can on
occasion tip the balance between a compensated and symptom-
atic state, for example, in patients with congestive heart failure.
Also, NSAIDs can interfere with the control of hypertension. In
treated hypertensive patients, NSAIDs can cause a modest
increase in both systolic and diastolic blood pressure. The
increase in blood pressure is independent of the type of antihy-
pertensive drug therapy [64—70]. This effect of NSAIDs is
probably adequately explained by their ability to cause fluid
retention and to decrease the production of vasodilatory pros-
taglandins.
Are there NSAIDs without renal side effects?
The sizable number of patients with risk factors for renal side
effects of NSAIDs has prompted the search for a kidney-sparing
NSAID. To some extent, and under certain conditions, the
NSAID sulindac causes fewer renal side effects than do other
NSAIDs [38, 62, 65, 71—74]. Initially it was thought that
sulindac "spared" renal prostaglandin synthesis because of its
requirement for hepatic conversion from the inactive prodrug
sulindac sulfoxide to the active sulindac sulfide [71]. This
explanation did not hold, especially as the kidney also can
activate the prodrug [75, 76]. Subsequently it has been pro-
posed that the lesser inhibition of renal prostaglandin synthesis
by sulindac might relate to inactivation of sulindac during renal
tubular secretion [76] and/or different susceptibility of pros-
taglandin synthase to sulindac in renal cortex versus medulla
[77]. In general, in patients at increased risk for NSAID-
induced renal side effects, sulindac produces fewer renal com-
plications. This is a relative finding, however, and renal side
effects such as vasomotor renal insufficiency and hyperkalemia
have been observed with sulindac [42, 74, 77—84]. Specifically
sulindac has a long half-life, and in patients with renal and liver
disease, the active sulindac sulfide can accumulate over days to
weeks and eventually reach levels that are 2 to 4 times higher
than those observed in patients with normal hepatic and renal
function [62, 77, 83, 84]. Again, consideration of the pharma-
codynamics of specific nonsteroidal drugs should help alert the
physician to potential side effects of NSAIDs and to the
expected time frame of their occurrence. A safe precaution
might be to check renal functional parameters in patients with
risk factors after a few days when using an NSAID with a short
half-life and after 1 to 2 weeks when using a drug with a long
half-life.
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Recently two types of prostaglandin synthases have been
cloned [20]. Their distribution varies within tissues [20]. In the
kidney the predominant form appears to be PGH synthase 2.
However, no segmental analysis of the intrarenal distribution of
the two isoforms of PGH synthase has been performed. This
analysis will be of interest, as the susceptibility of PGH
synthase 1 and synthase 2 for inhibition by specific NSAIDs
may vary by 50-fold. Potentially, PGH synthase isotype-spe-
cific NSAIDs can be designed and help to further reduce renal
problems from NSAIDs.
Questions and answers
DR. ALLEN KAPLAN (Chief, Department of Medicine, Uni-
versity Hospital, State University of New York at Stony Brook,
Stony Brook, New York): I was particularly interested in the
point you made about how NSAIDs can shunt arachidonic acid
into the synthesis of unusual metabolites, such as the one that
cross-reacts with the thromboxane receptor. Another possibil-
ity, of course, would be to shunt into the lipoxygenase pathway
leading to leukotrienes. Could you comment about whether that
happens in the kidney and whether such substances also might
have an effect on the syndrome you describe?
DR. SCHLONDORFF: Thank you for bringing up that point. As
Dr. Kaplan has stated, arachidonic acid is not only metabolized
by cyclooxygenase to prostanoids and by peroxidation to these
novel compounds, it also can be metabolized by a number of
other enzymes including lipoxygenase, epoxygenase, and
monooxygenase [20]. Specifically, the 5-lipoxygenase pathway
yields leukotrienes [85]. Normal renal tissue contains negligible
amounts of 5-lipoxygenase, which is expressed predominantly
in inflammatory cells [11, 85]. Therefore, under normal condi-
tions, shunting of arachidonic acid in the kidney generates few
leukotrienes. During disease processes with infiltration of in-
flammatory cells, however, shunting towards leukotrienes can
occur in the kidney and can become an important pathophysi-
ologic factor [86—91]. Specifically, leukotrienes C and D are
marked vasoconstrictors that also cause contraction of mesan-
gial cells, resulting in a decrease in renal blood flow and
glomerular filtration rate [92—95]. Thus during renal inflamma-
tory disease, inhibition of prostaglandins by NSAIDs and
concomitant increases in leukotrienes appear to contribute to
deterioration of renal function.
DR. LEONARD MEISELAS (Department of Medicine, Univer-
sity Hospital at Stony Brook): Consider, as an example, the
hypertensive patient being treated with a calcium-channel
blocker. Such a patient presumably already would have expe-
rienced a reduction in the tonicity of the afferent arteriole.
Would such a patient still be susceptible to the phenomenon
you have described?
DR. SCHLONDORFF: To the best of my knowledge, this
situation has not been examined in isolated arterioles or in
micropuncture studies. However, the effect of calcium-channel
blockers is obviously not 100%. They mitigate vasoconstriction
but do not eliminate it. The finding that control of hypertension
by calcium-channel blockers can be interfered with to some
extent by the addition of an NSAID indicates that vasodilatory
prostaglandins play a role even in the presence of vasodilatory
drugs [64].
DR. JORDAN J. COHEN (Dean, School of Medicine, State
University of New York at Stony Brook): Are the receptors
responsible for the vasomotor actions of prostaglandins the
same as the receptors responsible for the antiinflammatory
actions?
DR. SCHLONDORFF: There exist at least two types of POE2
receptors [20]. One receptor is linked by a stimulatory 0 protein
to adenylate cyclase and is responsible for vasodilation. In-
creasing intracellular cyclic AMP results in relaxation of vas-
cular smooth muscle [20]. The prostaglandin receptor causing
stimulation of cAMP is also involved in prostaglandin's immune
modulatory role [96]. A second type of prostaglandin receptor,
linked to a different G protein, can inhibit cAMP generation
[20]. The latter type of prostaglandin receptor may be respon-
sible for many of the tubular actions of prostaglandins [201.
DR. EDWARD BERGOFSKY (Head, Division of Pulmonary
Disease, University Hospital at Stony Brook): Most people now
believe that a major consideration in treating diabetic patients is
reducing the glomerular pressure, perhaps thereby retarding the
development of nephropathy. How does this consideration bear
on the susceptibility of diabetic patients to the adverse conse-
quence of nonsteroidal drugs? Should we be wary of using these
agents in diabetic patients?
DR. SCHLONDORFF: Prostaglandins probably contribute little
to hyperfiltration in patients with early diabetes [97]. I am not
aware of an increased risk of renal side effects from NSAIDs in
diabetic patients in general, with the exception of patients who
are volume-depleted secondary to uncontrolled diabetes, have
moderate renal insufficiency, and/or have an impaired ability to
excrete potassium. However, the group of diabetic patients
with mild renal insufficiency and some impairment of potassium
excretion is sizable. Furthermore, some patients with diabetic
nephropathy have reduced albumin levels with altered pharma-
cokinetics for NSAIDs, which may require adjustment of drug
dosage.
DR. COHEN: Are there classes of patients for whom nonste-
roidal agents are absolutely contraindicated, for whom atten-
tion to the dose and frequency of administration would not
suffice?
DR. SCHLONDORFF: I think that patients with active renal
disease should not be treated with an NSAID, not only because
of the vasomotor effects, but also because of the effects of
prostaglandins on inflammation [98]. As I've mentioned, pros-
taglandins have antiinflammatory actions. For example, POE2
and P012 suppress production of cytokines such as IL-I, IL-2
[96, 98, 99] and, as we've recently shown, that of monocyte
chemoattractant protein (MCP-1) and monocyte colony-stimu-
lating factor (CSF-l) as well [100]. In addition, prostaglandins
suppress proliferation of T-cells and leukocytes [96, 98]. There-
fore, in patients with active inflammatory renal disease, sup-
pression of prostaglandin synthesis would not only reduce renal
blood flow, but could even worsen the overall disease process,
as shown in animal studies [101—103]. On the other hand,
administration of pharmacologic doses of stable prostaglandin
analogues improves the disease process in kidneys of animals
with lupus, experimental glomerulonephritis, or tubulointersti-
tial disease [98, 104, 105].
Da. COHEN: You chose not to address a rare complication of
nonsteroidal drugs, namely, nephrotic syndrome with or with-
out interstitial nephritis. Could this complication also be linked
to prostaglandins?
DR. SCHLONDORFF: Perhaps that complication could be
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related to the role of prostaglandins as antiinflammatory agents
in chronic inflammatory processes, as Ijust discussed. I say this
because the nephrotic syndrome and interstitial nephritis occa-
sionally seen in these patients could represent a predominant
T-cell disorder [13, 141. We know that analysis of the inflam-
matory infiltrate in the kidneys of these patients has identified
about 90% as T-cells [14]. 1 already mentioned that administra-
tion of pharmacologic doses of stable prostaglandins can sup-
press the proliferation and infiltration of T-cells and other
inflammatory cells in experimental interstitial renal disease
[1051. A hypothetical scheme for the development of interstitial
nephritis in some patients after months on an NSAID could
involve mild ischemic or other local tubular damage with
release of antigens. The antigen released could then be pre-
sented by other proximal tubular cells, which can express MHC
class-2 surface antigens and present antigen [106]. This process
could initiate a local immune response that usually would be
self-limited and therefore would go unnoticed. In the continued
presence of an NSAID, the initial insult might be propagated
and, in the absence of prostaglandins, the pro-inflammatory
loop would be amplified by T-cell proliferation and by leuko-
triene and cytokine production, resulting theoretically in the
rare instances of acute interstitial nephritis with or without
nephrotic syndrome [13].
DR. EDWARD NORD (Division of Nephrology, University
Hospital at Stony Brook): What is the incidence of hyperkale-
mia as a complication of nonsteroidal drug administration in
individuals who do not have hyporeninemic hypoaldoster-
onism?
DR. SCHLONDORFF: In general, hyperkalemia with an
NSAID occurs in patients with an already impaired ability to
excrete potassium; that is, the NSAID just "pushes them over
the edge." A large proportion of these patients have a hypore-
nin-hypoaldosterone syndrome, but the exact incidence is not
known.
DR. ARTHUR BERKEN (Division of Oncology, University
Hospital at Stony Brook): Is there any evidence that mild
degrees of hydronephrosis, let's say in patients who have
significant benign prostatic hypertrophy but no evidence of
renal failure, predispose patients to the side effects of nonste-
roidal drugs?
DR. SCHLONDORFF: Let me start with the latter part of the
question. I am not aware that prostatic hypertrophy alone is a
risk factor for developing renal side effects from NSAIDs. I
guess that's because most patients still have an intact uretero-
vesical sphincter mechanism without reflux or hydronephrosis.
Certainly people who have acute or chronic obstructive ne-
phropathy would be at risk for developing side effects from an
NSAID. Studies have shown that hydronephrosis is accompa-
nied by increased renal prostaglandin production [107]. While
excess thromboxane might contribute to the decline of renal
function, the vasodilatory prostaglandins are important in main-
taining renal blood flow and function [107]. Furthermore, ob-
structive nephropathy impairs renal potassium secretion [58].
Therefore, inhibition of prostaglandin production by NSAIDs in
patients with hydronephrosis can worsen renal function and
cause hyperkalemia.
DR. MICHAEL GEHEB (Division of Nephrology, University
Hospital at Stony Brook): I am intrigued by the rapidity with
which hyperkalemia often occurs after the initiation of
NSAIDs. Because of its speed, I've always assumed that the
hyperkalemia was due to a transcellular shift of potassium. Has
a mechanism for such a shift been rigorously examined? For
example, have beta-adrenergic drugs or other physiologic reg-
ulators of transcellular potassium transport, such as insulin,
been evaluated as potential mediators of this complication?
DR. SCHLONDORFF: I am not aware that extrarenal handling
of potassium has been examined in great detail after NSAID
administration. Prostaglandins might have an effect on the
re-uptake of catecholamines at nerve endings, an effect that
could potentially influence extrarenal potassium handling. In
general, the hyperkalemia with NSAIDs can be accounted for
by a decline in the urinary excretion of potassium. For example,
the patient under discussion had a urinary potassium concen-
tration of 20 mEq/liter with a urinary volume of about one liter.
With a dietary intake of 60 to 80 mEq of potassium/day, he was
in positive potassium balance which, at a serum potassium of
6.4 mEq/liter, was clearly inappropriate.
DR. MICHAEL S. GOLIGORSKY (Division of Nephrology,
University Hospital at Stony Brook): Do nonsteroidal drugs
have any effect on nitric oxide generation in the kidney or in the
renal vasculature? Do you think the effect of nonsteroidal
agents is analogous to the effect of substances that reduce the
production of nitric oxide such as L-NMMA?
DR. SCHLONDORFF: You raise an excellent point. In Figure 1
the balance between vasoconstrictors and vasodilators included
endothelium-derived relaxing factor, that is, nitric oxide. Cer-
tainly nitric oxide is a major vasodilator that antagonizes the
action of vasoconstrictors also in the renal vasculature [108]. So
there are some parallels to the effects of prostaglandins. Do
NSAIDs affect the generation of EDRF? I'm not aware that
they do, but the increase in EDRF literature is so explosive that
I easily could have missed that information. Theoretically there
could be interactions. The generation of nitric oxide might be
influenced by free radicals. The cyclooxygenase reaction in-
cludes generation of free radicals, which is also inhibited by
NSAIDs [20].
DR. G0LIG0RsKY: Given that the rate-limiting step in pros-
taglandin generation appears to be release of arachidonic acid,
shouldn't activation of phospholipase A2 be necessary to see
the effects of an NSAID?
DR. SCHLONDORFF: That's correct. That was my point for
stressing that most renal vasomotor effects of NSAIDs occur
under conditions in which phospholipase A2 and thereby arachi-
donic acid release and prostaglandin synthesis are activated.
DR. SUZANNE FIELDS (Head, Division of Geriatrics, Univer-
sity Hospital at Stony Brook): Many elderly patients are being
treated with aspirin in an effort to prevent stroke. Is this
practice risky from the standpoint of renal insufficiency?
DR. SCHLONDORFF: I don't think so. In fact the small dosage
of aspirin used—a baby aspirin or 60 mg/day—was chosen
because at that dose, aspirin's effect remains predominantly
restricted to the inhibition of thromboxane generation by plate-
lets, without influencing endothelial or vascular smooth muscle
production of vasodilators such as prostacyclin and PGE2.
Aspirin's effect is "selective" because platelets do not have
nuclei and hence are incapable of synthesizing new proteins.
Aspirin irreversibly inactivates cyclooxygenase and renders a
platelet incapable of generating thromboxane for the rest of its
life span. In contrast, endothelial cells and vascular smooth
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muscle cells turn over cyclooxygenase rapidly; the cyclooxy-
genase inhibition achieved with low-dose aspirin is easily
overcome by de-novo cyclooxygenase generation.
DR. PIERCE GARDNER (Division of Infectious Disease, Uni-
versity Hospital at Stony Brook): I'm impressed with the large
number of groups we've identified who are at risk for compli-
cations from nonsteroidal drugs: diabetics with marginal renal
function, the large number of people treated with diuretic
and/or hypertensive agents, possibly patients with hyperurice-
mia. The decisions to begin giving nonsteroidal drugs and the
dosage to employ seem to be decisions that require some
thought. It also seems to me that we can identify people who are
likely to get into trouble. So, my specific question is: Should
NSAIDs be readily available as over-the-counter drugs without
someone assessing the potential risk and what the dose should
be?
DR. SCHLONDORFF: As I stated earlier, an enormous number
of people take NSAIDs, and the number of people who theo-
retically are at some risk is probably also extremely high. Yet
the number of renal side effects from NSAIDs remains small.
Even in otherwise-healthy octogenarians, NSAIDs need not
alter renal function [36, 44, 45]. Being at risk does not mean that
everyone is going to develop side effects. Furthermore, most
patients take an NSAID intermittently and for short periods of
time.
DR. FREDERICK J. KASKEL (Director, Division of Pediatric
Nephrology, University Hospital at Stony Brook): I have a
comment and a question. Premature and full-term infants with
patent ductus arteriosus customarily are treated with one or two
doses of indomethacin. These infants have a very high inci-
dence of vasomotor acute renal failure. I don't believe the
pharmacokinetics of the drug in the newborn have been studied
yet.
My question arises because I also am concerned about how
or whether nonsteroidal drugs potentiate or increase cyclospo-
rime toxicity. Studies suggest that abnormalities in the renal
prostaglandin system contribute to acute and chronic cyclospo-
rime toxicity [109, 110]. Could you comment about the use of
nonsteroidal drugs in a renal transplant patient treated with
cyclosporine?
DR. SCHLONDORFF: I consider patients taking cyclosporine
at risk for developing NSAID-induced renal insufficiency [111].
In terms of the cyclosporine toxicity, I think your lab and others
have shown that thromboxane contributes to the adverse renal
effects of that drug [110]. On the other hand, you might
remember a report suggesting that transplant patients taking
prostaglandin analogues for ulcer prophylaxis maintained better
renal function during treatment with cyclosponne [112]. Unfor-
tunately, subsequent studies have not confirmed the initial
report [113]. We would have to have a way of delivering
prostaglandins specifically to the kidney to produce a beneficial
effect on renal function.
DR. BARRY GRUBER (Division of Rheumatology, University
Hospital at Stony Brook): I have a brief comment. Obviously
we rheumatologists spend a lot of time administering these
drugs, but I would like to endorse the idea that these agents
probably are overused. We find that often we can avoid using
nonsteroidal agents for crystal-induced acute inflammatory
problems, and we are using more acetaminophen for degener-
ative joint disease. I also have two followups to Dr. Kaskel's
concerns. First, misoprostol is being used with increasing
frequency together with nonsteroidal drugs. Does this practice
reduce the risks of renal side effects? Second, you suggested
that elevated uric acid levels might interfere with the excretion
of NSAIDs. I would think that would be a two-way street: when
we give NSAIDs, we would expect an increase in serum uric
acid, yet clinically we don't see that.
DR. SCHLONDORFF: Regarding your first point: apart from
the studies in transplant patients, I am not aware of any renal
effects of misoprostol in patients taking NSAIDs. Again, I
would say that the circulating levels achieved with oral pros-
taglandin analogues are insufficient to affect renal function.
Concerning the potential competition for tubular secretion
between uric acid and NSAIDs, I am not aware that NSAIDs
increase uric acid levels. The hypothetical possibility of uric
acid and NSAIDs competing for secretion remains but need not
result in a discernible increase in uric acid levels. For example,
the affinity of uric acid for the transporter might be much higher
than that of the NSAID. Increased uric acid levels could lead to
decreased secretion of the NSAID without a further rise in uric
acid levels. You see, a nephrologist can always find a way out
through transport!
Reprint requests to Dr. D. Schlondorff, Director, Division of Ne-
phrology, Albert Einstein College of Medicine, 1300 Morris Park
Avenue, Bronx, New York 10461-1602, USA
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